Dr Reddy's Labs

{
  "main_header": {
    "sid": 734514,
    "name": "Dr Reddy's Labs",
    "stock_name": "Dr Reddy's Labs",
    "full_name": "Dr Reddys Laboratories Ltd",
    "name_url": "stocks-analysis/dr-reddy-s-labs",
    "exchange": 0,
    "exchangecode": "",
    "primexch": 1,
    "country_id": 34,
    "currency": "INR",
    "cmp": "1,310.50",
    "chg": 39.55,
    "chgp": "3.11%",
    "dir": 1,
    "prev_price": "1,270.95",
    "mcapval": "106,961.00 Cr",
    "mcap": "Large Cap",
    "scripcode": "500124",
    "symbol": "DRREDDY",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "India SENSEX",
    "isin": "INE089A01031",
    "curr_date": "May 06",
    "curr_time": "",
    "bse_nse_vol": "34.35 lacs",
    "exc_status": "Active",
    "traded_date": "May 06, 2026",
    "traded_date_str": "2026 05 06",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/dr-reddy-s-labs-734514-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Dr Reddys Laboratories Ltd Rallies 3.35% and Approaches 5-Day Moving Average Resistance",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-hits-intraday-high-with-335-surge-on-6-may-2026-3977932",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/DrReddysLaborat_priceRelatedfactors_3977932.png",
        "date": "2026-05-06 13:15:56",
        "description": "The Sensex declined by 0.17% on 6 Jun 2026, while Dr Reddys Laboratories Ltd surged 3.35%, outperforming its Pharmaceuticals & Biotechnology sector by 1.08 percentage points. This strong single-session gain marks a notable rebound after four consecutive days of decline, raising the question of whether this is a genuine recovery or a technical bounce within a broader trend."
      },
      {
        "title": "P/E at 19.05 vs Industry's 33.83: What the Data Shows for Dr Reddys Laboratories Ltd",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-navigating-nifty-50-membership-and-institutional-shifts-3977237",
        "imagepath": "",
        "date": "2026-05-06 09:21:03",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Valuation Picture: Discount Amid Sector Premiums</strong></p>\n                <p>The current P/E of <a href=\"https://www.marketsmojo.com/stocks-analysis/dr-reddy's-labs-734514-0\" class=\"stk\">Dr Reddys Laboratories Ltd</a> at 19.05 stands in stark contrast to the industry average of 33.83, indicating the stock is trading at a 44% discount relative to its sector peers. This valuation gap is particularly striking given the Pharmaceuticals & Biotechnology sector’s reputation for commanding premium multiples due to growth prospects and defensive qualities. The discount may reflect concerns over recent performance or broader market sentiment, but it also suggests the stock is priced with a margin of safety compared to its industry cohort. <a href=\"https://www.marketsmojo.com/stocks-..."
      },
      {
        "title": "Dr Reddys Laboratories Downgraded to Hold Amid Mixed Financial and Technical Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/dr-reddys-laboratories-downgraded-to-hold-amid-mixed-financial-and-technical-signals-3975292",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/DrReddysLaborat_mojoScore_3975292.png",
        "date": "2026-05-05 08:51:45",
        "description": "Dr Reddys Laboratories Ltd, a prominent player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Buy to Hold as of 4 May 2026. This adjustment reflects a nuanced assessment across four key parameters: quality, valuation, financial trend, and technicals. Despite strong long-term fundamentals, recent quarterly results and evolving technical indicators have tempered investor enthusiasm, prompting a more cautious stance."
      },
      {
        "title": "Dr Reddys Laboratories Ltd Sees Technical Momentum Shift Amid Mixed Market Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-sees-technical-momentum-shift-amid-mixed-market-signals-3974841",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/DrReddysLaborat_technicaldot_3974841.png",
        "date": "2026-05-05 08:04:41",
        "description": "Dr Reddys Laboratories Ltd has experienced a notable shift in its technical momentum, moving from a bullish to a mildly bullish stance. This transition is underscored by a complex interplay of technical indicators, including MACD, RSI, moving averages, and Bollinger Bands, which collectively suggest a nuanced outlook for the pharmaceutical giant amid recent market fluctuations."
      },
      {
        "title": "P/E at 19.83 vs Industry's 33.40: What the Data Shows for Dr Reddys Laboratories Ltd",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-navigating-nifty-50-membership-amid-institutional-shifts-3973318",
        "imagepath": "",
        "date": "2026-05-04 10:30:37",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Valuation Picture: Discount Amidst Sector Premiums</strong></p>\n                <p>The current P/E of 19.83 for <a href=\"https://www.marketsmojo.com/stocks-analysis/dr-reddy's-labs-734514-0\" class=\"stk\">Dr Reddys Laboratories Ltd</a> stands well below the industry average of 33.40, indicating a valuation discount of nearly 40.6%. This gap suggests that the market is pricing in either a more conservative growth outlook or perceived risks relative to peers. The Pharmaceuticals & Biotechnology sector often commands premium valuations due to its growth potential and innovation pipeline, yet <a href=\"https://www.marketsmojo.com/stocks-analysis/dr-reddy's-labs-734514-0\" class=\"stk\">Dr Reddys Laboratories Ltd</a> remains valued more modestly. This divergence raises the question of wh..."
      },
      {
        "title": "P/E at 19.96 vs Industry's 33.42: What the Data Shows for Dr Reddys Laboratories Ltd",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-navigating-nifty-50-membership-and-institutional-dynamics-3969660",
        "imagepath": "",
        "date": "2026-04-30 09:20:50",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Significance of Nifty 50 Membership</strong></p>\n                <p>As a constituent of the Nifty 50, Dr Reddys Laboratories Ltd holds a pivotal role in representing the Pharmaceuticals & Biotechnology sector within India’s premier equity benchmark. This membership not only enhances the stock’s visibility among domestic and international investors but also ensures inclusion in numerous index-tracking funds and exchange-traded funds (ETFs). The company’s market capitalisation of ₹1,11,063.63 crores firmly places it in the large-cap category, reinforcing its weight within the index and its influence on overall market movements.</p>\n                <p>Being part of the Nifty 50 also subjects Dr Reddys Laboratories to heightened scrutiny and performance expectations. The index’s c..."
      },
      {
        "title": "P/E at 20.31 vs Industry's 33.32: What the Data Shows for Dr Reddys Laboratories Ltd",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-strengthens-position-as-key-nifty-50-constituent-amid-institutional-interest-3967724",
        "imagepath": "",
        "date": "2026-04-29 09:20:49",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Significance of Nifty 50 Membership</strong></p>\n                <p>Being a constituent of the Nifty 50 index confers considerable advantages on Dr Reddys Laboratories Ltd, not least in terms of enhanced visibility and liquidity. The index, widely regarded as the benchmark for Indian equity markets, attracts significant passive investment flows from index funds and exchange-traded funds (ETFs). Consequently, inclusion ensures a steady demand for the stock, which can help stabilise price movements and reduce volatility.</p>\n                <p>Dr Reddys Laboratories, with a market capitalisation of approximately ₹1,12,353.17 crores, is classified as a large-cap stock, making it a cornerstone holding for many institutional portfolios. Its presence in the Nifty 50 also signals a l..."
      },
      {
        "title": "P/E at 20.00 vs Industry's 33.33: What the Data Shows for Dr Reddys Laboratories Ltd",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-strengthens-position-amid-nifty-50-membership-and-institutional-interest-3966031",
        "imagepath": "",
        "date": "2026-04-28 09:20:49",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Valuation Picture: Discount Amidst Sector Premiums</strong></p>\n                <p><a href=\"https://www.marketsmojo.com/stocks-analysis/dr-reddy's-labs-734514-0\" class=\"stk\">Dr Reddys Laboratories Ltd</a> trades at a P/E of 20.00, markedly below the Pharmaceuticals & Biotechnology industry average of 33.33. This 40% discount suggests the market is pricing in either a more conservative growth outlook or risk factors not fully reflected in sector valuations. The sizeable premium commanded by peers in the industry contrasts with <a href=\"https://www.marketsmojo.com/stocks-analysis/dr-reddy's-labs-734514-0\" class=\"stk\">Dr Reddys Laboratories Ltd</a>’s more modest multiple, raising questions about the sustainability of this valuation gap — <a href=\"https://www.marketsmojo.com/stock..."
      },
      {
        "title": "P/E at 19.67 vs Industry's 32.51: What the Data Shows for Dr Reddys Laboratories Ltd",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-strengthens-position-as-key-nifty-50-constituent-amid-robust-institutional-interest-3963830",
        "imagepath": "",
        "date": "2026-04-27 09:20:48",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Valuation Picture: Discount Amidst Sector Premiums</strong></p>\n                <p>The current P/E of 19.67 for <a href=\"https://www.marketsmojo.com/stocks-analysis/dr-reddy's-labs-734514-0\" class=\"stk\">Dr Reddys Laboratories Ltd</a> stands in stark contrast to the industry average of 32.51, signalling a valuation discount of nearly 40%. This divergence suggests the market is pricing in either a more conservative growth outlook or perceived risks relative to its pharmaceutical peers. The sector’s elevated P/E typically reflects expectations of robust earnings growth and innovation, yet <a href=\"https://www.marketsmojo.com/stocks-analysis/dr-reddy's-labs-734514-0\" class=\"stk\">Dr Reddys Laboratories Ltd</a> appears to be trading on more subdued multiples. This valuation gap invi..."
      }
    ],
    "total": 545,
    "sid": "734514",
    "stock_news_url": "https://www.marketsmojo.com/news/dr-reddys-laboratories-734514"
  },
  "announcements": [
    {
      "caption": "Disclosure Under Regulation 30 Of SEBI (LODR) Regulations 2015",
      "datetime": "29-Apr-2026",
      "details": "Disclosure under Regulation 30 of SEBI (LODR) Regulations 2015",
      "source": "BSE"
    },
    {
      "caption": "Clarification-Disclosure Under Regulation 30 Of SEBI (LODR) Regulations 2015",
      "datetime": "24-Apr-2026",
      "details": "Disclosure under Regulation 30 of SEBI (LODR) Regulations 2015",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release",
      "datetime": "24-Apr-2026",
      "details": "Intimation of Earnings call",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "",
      "data": [
        {
          "title": "BOARD MEETING",
          "txt": "12 May 2026"
        }
      ]
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Dr Reddys Laboratories Ltd has declared <strong>800%</strong> dividend, ex-date: 10 Jul 25",
          "dt": "2025-07-10",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "",
      "data": [
        {
          "txt": "Dr Reddys Laboratories Ltd has announced <strong>1:5</strong> stock split, ex-date: 28 Oct 24",
          "dt": "2024-10-28",
          "middle_text": "Split"
        }
      ]
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "",
      "data": [
        {
          "txt": "Dr Reddys Laboratories Ltd has announced <strong>1:1</strong> bonus issue, ex-date: 28 Aug 06",
          "dt": "2006-08-28",
          "middle_text": "Bonus Alert"
        }
      ]
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Dr Reddys Laboratories Ltd Rallies 3.35% and Approaches 5-Day Moving Average Resistance

2026-05-06 13:15:56

The Sensex declined by 0.17% on 6 Jun 2026, while Dr Reddys Laboratories Ltd surged 3.35%, outperforming its Pharmaceuticals & Biotechnology sector by 1.08 percentage points. This strong single-session gain marks a notable rebound after four consecutive days of decline, raising the question of whether this is a genuine recovery or a technical bounce within a broader trend.

Read full news article

P/E at 19.05 vs Industry's 33.83: What the Data Shows for Dr Reddys Laboratories Ltd

2026-05-06 09:21:03

Valuation Picture: Discount Amid Sector Premiums

The current P/E of Dr Reddys Laboratories Ltd at 19.05 stands in stark contrast to the industry average of 33.83, indicating the stock is trading at a 44% discount relative to its sector peers. This valuation gap is particularly striking given the Pharmaceuticals & Biotechnology sector’s reputation for commanding premium multiples due to growth prospects and defensive qualities. The discount may reflect concerns over recent performance or broader market sentiment, but it also suggests the stock is priced with a margin of safety compared to its industry cohort. Read full news article

Dr Reddys Laboratories Downgraded to Hold Amid Mixed Financial and Technical Signals

2026-05-05 08:51:45

Dr Reddys Laboratories Ltd, a prominent player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Buy to Hold as of 4 May 2026. This adjustment reflects a nuanced assessment across four key parameters: quality, valuation, financial trend, and technicals. Despite strong long-term fundamentals, recent quarterly results and evolving technical indicators have tempered investor enthusiasm, prompting a more cautious stance.

Read full news article

Dr Reddys Laboratories Ltd Sees Technical Momentum Shift Amid Mixed Market Signals

2026-05-05 08:04:41

Dr Reddys Laboratories Ltd has experienced a notable shift in its technical momentum, moving from a bullish to a mildly bullish stance. This transition is underscored by a complex interplay of technical indicators, including MACD, RSI, moving averages, and Bollinger Bands, which collectively suggest a nuanced outlook for the pharmaceutical giant amid recent market fluctuations.

Read full news article

P/E at 19.83 vs Industry's 33.40: What the Data Shows for Dr Reddys Laboratories Ltd

2026-05-04 10:30:37

Valuation Picture: Discount Amidst Sector Premiums

The current P/E of 19.83 for Dr Reddys Laboratories Ltd stands well below the industry average of 33.40, indicating a valuation discount of nearly 40.6%. This gap suggests that the market is pricing in either a more conservative growth outlook or perceived risks relative to peers. The Pharmaceuticals & Biotechnology sector often commands premium valuations due to its growth potential and innovation pipeline, yet Dr Reddys Laboratories Ltd remains valued more modestly. This divergence raises the question of wh...

Read full news article

P/E at 19.96 vs Industry's 33.42: What the Data Shows for Dr Reddys Laboratories Ltd

2026-04-30 09:20:50

Significance of Nifty 50 Membership

As a constituent of the Nifty 50, Dr Reddys Laboratories Ltd holds a pivotal role in representing the Pharmaceuticals & Biotechnology sector within India’s premier equity benchmark. This membership not only enhances the stock’s visibility among domestic and international investors but also ensures inclusion in numerous index-tracking funds and exchange-traded funds (ETFs). The company’s market capitalisation of ₹1,11,063.63 crores firmly places it in the large-cap category, reinforcing its weight within the index and its influence on overall market movements.

Being part of the Nifty 50 also subjects Dr Reddys Laboratories to heightened scrutiny and performance expectations. The index’s c...

Read full news article

P/E at 20.31 vs Industry's 33.32: What the Data Shows for Dr Reddys Laboratories Ltd

2026-04-29 09:20:49

Significance of Nifty 50 Membership

Being a constituent of the Nifty 50 index confers considerable advantages on Dr Reddys Laboratories Ltd, not least in terms of enhanced visibility and liquidity. The index, widely regarded as the benchmark for Indian equity markets, attracts significant passive investment flows from index funds and exchange-traded funds (ETFs). Consequently, inclusion ensures a steady demand for the stock, which can help stabilise price movements and reduce volatility.

Dr Reddys Laboratories, with a market capitalisation of approximately ₹1,12,353.17 crores, is classified as a large-cap stock, making it a cornerstone holding for many institutional portfolios. Its presence in the Nifty 50 also signals a l...

Read full news article

P/E at 20.00 vs Industry's 33.33: What the Data Shows for Dr Reddys Laboratories Ltd

2026-04-28 09:20:49

Valuation Picture: Discount Amidst Sector Premiums

Dr Reddys Laboratories Ltd trades at a P/E of 20.00, markedly below the Pharmaceuticals & Biotechnology industry average of 33.33. This 40% discount suggests the market is pricing in either a more conservative growth outlook or risk factors not fully reflected in sector valuations. The sizeable premium commanded by peers in the industry contrasts with Dr Reddys Laboratories Ltd’s more modest multiple, raising questions about the sustainability of this valuation gap — Read full news article

P/E at 19.67 vs Industry's 32.51: What the Data Shows for Dr Reddys Laboratories Ltd

2026-04-27 09:20:48

Valuation Picture: Discount Amidst Sector Premiums

The current P/E of 19.67 for Dr Reddys Laboratories Ltd stands in stark contrast to the industry average of 32.51, signalling a valuation discount of nearly 40%. This divergence suggests the market is pricing in either a more conservative growth outlook or perceived risks relative to its pharmaceutical peers. The sector’s elevated P/E typically reflects expectations of robust earnings growth and innovation, yet Dr Reddys Laboratories Ltd appears to be trading on more subdued multiples. This valuation gap invi...

Read full news article

View All News